Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
145 hedge funds and large institutions have $1.85B invested in Apellis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 49 reducing their positions, and 18 closing their positions.
29% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $3.67M
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
2% more funds holding
Funds holding: 142 → 145 (+3)
1.17% more ownership
Funds ownership: 81.03% → 82.2% (+1.2%)
2% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 49
7% less capital invested
Capital invested by funds: $2B → $1.85B (-$149M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.9M |
| 2 |
Jennison Associates
New York
|
+$21.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.6M |
| 4 |
JP Morgan Chase
New York
|
+$18M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$25.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$25.1M |
| 3 |
EP
Eversept Partners
New York
|
-$10.1M |
| 4 |
Two Sigma Investments
New York
|
-$7.13M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.87M |
APLS Hedge Fund Activity: Q3 2020 in Review
145 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2020, worth a combined $1.85B — down 7.4% from $2B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new APLS positions and 18 closed out — a net gain of 3 holders — while 50 added to existing stakes and 49 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $24.9M. The largest seller was Fidelity International, cutting an estimated $25.4M.
- 145 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2020, up from 142 in Q2 2020.
- Funds reported $1.85B of Apellis Pharmaceuticals stock for Q3 2020, down 7.4% quarter-over-quarter.
- 21 funds opened new Apellis Pharmaceuticals positions in Q3 2020 and 18 closed out, a net change of +3 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2020 was Citadel Advisors, an estimated $24.9M added.
- The largest Apellis Pharmaceuticals seller in Q3 2020 was Fidelity International, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2020.